The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and degradation. Ubiquitination of p53 is regulated by ARF, which binds to MDM2 and inhibits its E3 ligase function. P53 is also subjected to modification by conjugation of SUMO-1. We found that a p53 mutant deficient for MDM2 binding (p53
Introduction
The p53 protein is regulated by multiple mechanisms, which is critical for its ability to respond to stress and function as a tumor suppressor. p53 turnover is regulated by MDM2, which functions as a ubiquitin E3 ligase to promote p53 ubiquitination and degradation by the proteasome (Zhang and Xiong, 2001) . Stress signals such as DNA damage induce p53 accumulation by phosphorylation (Prives and Hall, 1999) . Mitogenic signals activate p53 by induction of the ARF tumor suppressor encoded by an alternative open reading frame in the p16INK4a locus, which inhibits the E3 ligase function of MDM2 (Sherr, 1998; Zhang and Xiong, 2001) . MDM2 also regulates the acetylation of p53 by preventing binding of p300/CBP or recruitment of HDAC1 (Ito et al., 2001 (Ito et al., , 2002 Kobet et al., 2002) .
Recently, p53 and MDM2 have been found to be modified by small ubiquitin-like modifier (SUMO)-1 conjugation (Gostissa et al., 1999; Rodriguez et al., 1999; Muller et al., 2002; Xirodimas et al., 2002b) . Sumoylation of p53 and MDM2 in vitro is carried out by a universal SUMO-activating E1 enzyme (SEA1/SEA2 heterodimer) and SUMO-conjugating enzyme E2 (ubc9) (Hochstrasser, 2002) . SUMO is activated in an ATPdependent manner by E1, transferred to E2, and subsequently attached to the e-amino group of lysines on target proteins (Hochstrasser, 2002) . The sumoylated lysine residue in many substrates often locates within a consensus sequence of cK Â E, where c is an aliphatic residue (Rodriguez et al., 2002) . Lysine 386 is the major sumoylation site for p53 (Gostissa et al., 1999; Rodriguez et al., 1999) , whereas the sumoylation site on MDM2 has not been positively identified (Xirodimas et al., 2002b) .
The functional role of sumoylation is diverse among different substrates. It has been proposed to be important for regulating the localization, activity, and degradation of target proteins (Hochstrasser, 2002) . Initial studies using p53 386 lysine-to-arginine mutant resistant to sumoylation suggested that sumoylation moderately enhances p53 transcription activity (Gostissa et al., 1999; Rodriguez et al., 1999) . Other studies did not observe such an effect (Kwek et al., 2002; Minty et al., 2002) , possibly due to different assay conditions. Muller et al. (2002) found that the p53 386K mutant has slightly impaired apoptotic activity. It is possible that sumoylation also has other effects on p53 that are not evident in currently available functional assays.
Several proteins have been found to enhance the efficiency of sumoylation in vitro and in vivo, which is similar to the E3 ligase in the ubiquitination pathway (Hochstrasser, 2002) . The RING domain protein PIAS1 has been shown to stimulate p53 and MDM2 sumoylation (Kahyo et al., 2002; Miyauchi et al., 2002; Schmidt and Muller, 2002) . MDM2 sumoylation level is also stimulated by ARF through an unknown mechanism (Xirodimas et al., 2002b) . SUMO-1, E1, and E2 mainly localize within the nucleus; in vivo sumoylation requires nuclear localization of the substrate (Rodriguez et al., 2002) . Therefore, sumoylation may also be regulated by targeting substrates to the nucleus or nuclear substructures. Furthermore, removal of conjugated SUMO-1 by proteases may also play an important role in determining the level of sumoylation (Gong et al., 2002) .
An important regulator of p53 stability is the ARF tumor suppressor (Sherr, 1998; Zhang and Xiong, 2001) . ARF binds to MDM2 and inhibits its ability to promote p53 ubiquitination. ARF also promotes MDM2 localization into the nucleolus (Weber et al., 1999) . Human p14ARF contains a nucleolar localization signal (NoLS) in the C-terminal region of the protein encoded by exon 2 (Zhang and Xiong, 1999) . The N-terminus of p14ARF contains the MDM2-binding domain, sufficient to inhibit the E3 ligase function of MDM2 in vitro and stabilize p53 in vivo (Llanos et al., 2001; Midgley et al., 2001) . Therefore, the C-terminal region of ARF including the NoLS is not essential for regulation of p53 ubiquitination by MDM2. However, deletion of this signal sequence reduces the ability of ARF to stabilize p53 in vivo (Zhang and Xiong, 1999) , suggesting that it contributes to the efficient regulation of p53.
In addition to the NoLS sequence on ARF, MDM2 also has a cryptic NoLS sequence (residue 466-473) in its C-terminal RING domain (Lohrum et al., 2001) . Although this cryptic NoLS is not sufficient to target MDM2 to the nucleolus in the absence of ARF, it is important for targeting the MDM2-ARF complex to the nucleolus (Weber et al., 2000) . It has been proposed that binding of ARF to MDM2 induces conformational changes and exposes the cryptic NoLS on MDM2. Deletion of an internal region in the MDM2 D222-437 mutant appears to expose the cryptic NoLS and enables the mutant to accumulate to the nucleolus in the absence of ARF (Lohrum et al., 2001) .
In this report, we show that MDM2 and ARF expression increase the level of sumoylated p53. This activity requires a conserved sequence adjacent to the NoLS in the C-terminal domain of ARF and correlates with targeting of p53 to the nucleolus in the presence of MDM2. However, direct targeting of p53 to the nucleolus by fusion with an NoLS sequence does not substitute for the role of ARF or complement the ARF N-terminal fragment. These results show that the ARF C-terminal domain has unique functions in regulating p53 sumoylation.
Results

ARF and MDM2 coexpression increase the level of p53 sumoylation
To determine whether MDM2 and ARF regulate p53 sumoylation, we used an in vivo sumoylation assay described by Rodriguez et al. (1999) . The expression vector of His6-SUMO-1 was cotransfected with p53, MDM2, and ARF into H1299 cells, which is p53-null and expresses low levels of endogenous MDM2 and ARF. Proteins conjugated to His6-SUMO-1 were purified using Ni 2 þ -NTA beads under denaturing conditions. Sumoylated p53 and MDM2 were detected by Western blot of Ni 2 þ -NTA purified proteins. The result showed that a small fraction (o5%) of transfected p53 was mainly conjugated to a single SUMO-1 molecule. The level of p53 sumoylation was stimulated moderately by coexpression of MDM2 or ARF, but significantly enhanced by coexpression of both MDM2 and ARF (Figure 1a , top panel). MDM2 and ARF coexpression also stimulated the appearance of a higher molecular weight band above the monosumoylated p53, suggesting that an additional site on p53 may be modified as well. The stimulating effect of MDM2 was specific and was not observed using its homolog MDMX (data not shown). Identical results were also observed using the ARF-deficient cell line U2OS (data not shown). H1299 cells were chosen for subsequent experiments due to their higher transfection efficiency.
Confirming results described in a recent paper (Xirodimas et al., 2002b) , human MDM2 was also conjugated to His6-SUMO1 in vivo, appearing as a pair of bands above 110 kDa ( Figure 1b ). This is consistent with the addition of one SUMO-1 to human MDM2, which normally migrates near 97 kDa in its unmodified form. Expression of ARF with MDM2 strongly stimulated the sumoylation level of MDM2 (Figure 1b ). This effect was not simply due to stabilization of MDM2 by ARF, since MG132 was used in this experiment to induce MDM2 accumulation to similar levels in the presence or absence of ARF. Therefore, ARF strongly enhances MDM2 sumoylation and cooperates with MDM2 to stimulate p53 sumoylation in vivo.
Since the in vivo sumoylation assay involved ectopic expression of His6-SUMO1, we wanted to determine whether p53 conjugation to endogenous SUMO1 was also stimulated by MDM2 and ARF. Although SUMO1-modified forms of many proteins can be detected in direct Western blots as a minor band B10 kDa above the unmodified protein, use of such an approach on p53 is problematic, since monoubiquitinated p53 also appears at the same region. Initial attempts to immunoprecipitate endogenous p53 from ARF adenovirus-infected U2OS cells in the presence of isopeptidase inhibitor iodoacetamide, followed by anti-SUMO1 Western blot, did not detect a specific signal (not shown). This may be due to limited sensitivity of the SUMO1 antibody and the inability to prevent desumoylation after cell lysis. Therefore, we transfected H1299 cells with His6-tagged p53, which allowed denaturing purification of p53 by Ni-NTA beads. Endogenous SUMO1 conjugated to His6-p53 was then detected by anti-SUMO1 blot. Using this assay, p53 sumoylation was readily detectable when stimulated by ARF and wild-type MDM2 (Figure 1c) , and even more strongly by the MDM2 mutant D222-437 (more below). Importantly, cotransfection of HA-SUMO1 showed that the conjugation efficiency to ectopic SUMO1 was comparable to endogenous SUMO1. Therefore, ectopic SUMO1 expression did not lead to significant change of sumoylation efficiency.
MDM2-p53 binding is required for promoting p53 sumoylation
To identify the domain of MDM2 important for promoting p53 sumoylation, a panel of MDM2 mutants was analysed (Chen et al., 1995) . The results showed that MDM2 mutants that did not bind p53 or did not contain the NLS sequence failed to promote p53 sumoylation in the presence of ARF (Figure 2a) . The RING domain of MDM2 could be deleted without losing the p53 sumoylation function. Interestingly, the MDM2 D222-437 mutant had a much stronger ability to promote p53 sumoylation than wild-type MDM2, despite losing the ARF-binding site. This could be related to its intrinsic nucleolar localization function and unique structure (Figure 2a and more in Figure 6 ). Therefore, the results showed that the ability of MDM2 to enter the nucleus and bind p53 is important for promoting p53 sumoylation in the presence of ARF.
Since MDM2 sumoylation was readily detectable when coexpressed with ARF, we also examined sumoylation level of the MDM2 deletion mutants after cotransfection with ARF in an attempt to map the sumoylation site on MDM2. The results showed that all deletion mutants described above except the MDM2 D150-230 mutant could be efficiently sumoylated (data not shown). Since the MDM2 D150-230 mutant is localized in the cytoplasm due to loss of NLS signal (Chen et al., 1995) , lack of sumoylation could be due to failure to enter the nucleus or loss of a sumoylated lysine residue within this region. Therefore, this region was further analysed (see Figure 4 below).
ARF C-terminal region is important for stimulating p53 sumoylation
Next, a panel of ARF mutants was used to identify the region important for stimulating p53 sumoylation. The results showed that in addition to the N-terminal MDM2-binding domain, the sequence located between 102 and 116 of ARF was also important for stimulating p53 sumoylation (Figure 3a ). This region is highly conserved between human and mouse ARF (12/ 16 ¼ 75% identity) compared to the adjacent NoLS sequence (85-101, 7/17 ¼ 41% identity) (Zhang and Xiong, 1999) , suggesting that it may have functions related to the regulation of p53. The tumor-derived ARF 98Q point mutant that retains significant nucleolar targeting function was almost as efficient as wild type in promoting p53 sumoylation.
Since ARF strongly stimulated MDM2 sumoylation, the ARF mutants were also analysed for this function. The results indicated a critical requirement for the NoLS MDM2-ARF complex regulates p53 sumoylation L Chen and J Chen sumoylation, did not significantly affect MDM2 sumoylation ( Figure 3b ). Therefore, distinct regions in the ARF C-terminus are required for regulation of MDM2 and p53 sumoylation. The effect of ARF on p53 sumoylation level is mediated through binding to MDM2.
The N-terminal region of ARF (1-20) contains the MDM2-binding site and is sufficient to inhibit MDM2 ubiquitin E3 ligase function and stabilize p53 both in vitro and in vivo. We tested the ability of the ARF mutants to inhibit p53 ubiquitination. The results confirmed that the 1-64 fragment of ARF was sufficient for inhibiting p53 ubiquitination by MDM2, although this fragment did not enhance p53 sumoylation (Figure 3c) . Therefore, the C-terminal domain of ARF has a distinct function in regulating p53 and MDM2 sumoylation, but is dispensable for inhibiting p53 ubiquitination by MDM2.
ARF and MDM2 stimulate sumoylation of p53 lysine 386
Previous studies identified lysine 386 of p53 as the target for sumoylation (Gostissa et al., 1999; Rodriguez et al., 1999) . To test whether ARF and MDM2 promote modification of this site, a p53 386R mutant was tested. In vivo sumoylation of p53 386R was significantly reduced compared to wild-type p53 when expressed alone or coexpressed with MDM2 and ARF (Figure 4a ), suggesting that lysine 386 is the major sumoylation site targeted by MDM2 and ARF. However, weak sumoylation was still detectable with the p53 386R mutant after coexpression with MDM2 and ARF, indicating the presence of an alternative sumoylation site. A cytoplasmic MDM2 182R mutant (see below) promoted p53 sumoylation very poorly, whereas the nuclear MDM2
185R mutant retained the function (Figure 4a ), indicating that nuclear translocation of MDM2 is also important for promoting p53 sumoylation.
Since the MDM2 D150-230 mutant was not sumoylated in vivo, it could be due to loss of the NLS or a major sumoylation site. There are two lysine residues located within 150-230 (182 and 185 K), neither in a context optimal for sumoylation. When residue 182 was mutated to arginine, sumoylation of MDM2 182R in the presence of ARF was significantly reduced (Figure 4b ). However, immunofluorescence staining revealed that this mutant protein was localized in the cytoplasm, probably because 182 K is part of the NLS sequence (Figure 4c) . Therefore, nuclear entry is also critical for efficient sumoylation of MDM2. However, lysine 182 is unlikely to be the major sumoylation site. It is apparent that no single lysine residue in MDM2 is essential for ARFpromoted sumoylation, suggesting that alternative lysines can be used for conjugation in different mutants. A similar conclusion was reached by another recently published study (Miyauchi et al., 2002 ). Rodriguez et al., 1999) . Since our results showed that MDM2 expression increased the level of sumoylated p53 in vivo, we tested the importance of MDM2 binding in vivo using the p53 14Q19S double-point mutant which does not interact with MDM2 (Lin et al., 1994) . When transfected into H1299 cells, which express endogenous MDM2 and ARF, wild-type p53 sumoylation was readily detectable. However, p53
14Q19S was very poorly sumoylated although it was expressed at levels comparable to wild-type p53 (Figure 5a) . Cotransfection of p53
14Q19S with ectopic MDM2 and ARF also failed to promote its sumoylation. Therefore, MDM2 binding is important for efficient sumoylation of p53 or accumulation of sumoylated p53 in vivo. Since wild-type p53 and p53 14Q19S mutant sumoylation levels were significantly different without cotransfection of ARF and MDM2, it indicated that endogenous MDM2 and ARF play important roles in regulating the level of p53 sumoylation.
To test whether the effect of ARF and MDM2 on p53 sumoylation can be recapitulated in a cell-free system, we carried out in vitro sumoylation reactions using purified ubc9, SUMO-1, cellular fraction containing E1 activity, and in vitro translated p53, MDM2, and ARF proteins. Sumoylation of p53 and MDM2 were readily detected in this in vitro system (Figure 5b ). Unlike the in vivo assay, p53 14Q19S was sumoylated in vitro at the same efficiency as wild-type p53. Furthermore, addition of MDM2 and ARF to the reaction did not enhance sumoylation of p53. A caveat of this experiment was that formation of the p53-MDM2-ARF trimeric complex in vitro may be inefficient. However, the MDM2 D222-437 mutant that strongly stimulated p53 sumoylation in vivo independent of ARF (Figures 2 and 6) also had no effect on p53 in vitro (Figure 5b ), although it can efficiently bind to p53 in vitro (not shown). Therefore, the results suggested that inefficient sumoylation of p53 14Q19S in vivo was not simply due to its inability to interact with ubc9. It is possible that MDM2 and ARF stimulate p53 sumoylation through novel mechanisms in vivo or act at steps after sumo conjugation to prevent desumoylation of p53. As revealed in the experiments below, stimulation of p53 sumoylation by MDM2 and ARF in vivo involves nucleolar targeting, which was not simulated by the in vitro sumoylation assay. D222-437 were detected by the 4B11 antibody. Sumoylation of wild-type MDM2 was strongly stimulated by ARF, whereas MDM2 D222-437 was efficiently sumoylated in the absence of cotransfected ARF
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A nucleolar MDM2 mutant promotes p53 sumoylation without ARF As shown in Figures 2a and 5b , the MDM2 D222-437 mutant was highly efficient in promoting p53 sumoylation in vivo but had no effect in vitro. Interestingly, this mutant has been shown to accumulate in the nucleolus in the absence of ARF (Lohrum et al., 2001) . This was attributed to the presence of a cryptic NoLS sequence within the RING domain of MDM2, which may be exposed in the MDM2 D222-437 mutant without binding to ARF. Since the ability of ARF to stimulate p53 and MDM2 sumoylation also requires its NoLS and adjacent sequences, it is possible that nucleolar targeting is important for regulating the level of p53 sumoylation.
We tested whether the MDM2 D222-437 mutant was able to increase the level of sumoylated p53 without coexpression of ARF. The result showed that MDM2 D222-437 alone was highly active in stimulating p53 sumoylation in H1299 cells, which greatly exceeded that achieved by cotransfection of MDM2 and ARF (Figure 6a ). Addition of ARF only slightly increased p53 sumoylation by MDM2 D222-437 . The p53 14Q19S mutant was not sumoylated by MDM2 D222-437 , suggesting that it also functioned by binding to p53. The same results were also observed in ARF-deficient U2OS cells (data not shown). Using antibody 4B11 that can efficiently detect MDM2
D222-437 , we found that in U2OS cells, MDM2
D222-437 was sumoylated in vivo in the absence of ARF coexpression (Figure 6b ). In contrast, efficient sumoylation of wild-type MDM2 required cotransfection of ARF.
Next, the localization of p53 and MDM2 was examined by double-fluorescence staining in U2OS cells (Figure 7) . Coexpression of MDM2 and ARF clearly targeted wild-type p53 to the nucleolus in a fraction of the transfected cells (B20%). Deletion of 102-116 of ARF abrogated its ability to target p53 to the nucleolus in the triple transfection. In contrast, in the absence of cotransfected p53, targeting MDM2 to the nucleolus by ARF only required the 82-101 NoLS region but not the 102-116 sequence (data not shown). The MDM2 D222-437 mutant not only accumulated in the nucleolus in the absence of ARF; it also targeted a fraction of p53 to the nucleolus (Figure 7) . These results showed that nucleolar targeting of p53 by ARF required the conserved 102-116 region, which was also important for promoting p53 sumoylation. Double staining using anti-SUMO1 antibody also showed that p53-MDM2-ARF triple transfection caused the nucleolus to stain positive for SUMO1 (data not shown), suggesting that nucleolar p53 and MDM2 are conjugated to SUMO1.
Direct targeting of p53 to the nucleolus facilitates sumoylation in the presence of ARF and MDM2
The correlation between p53 nucleolar localization and sumoylation raised the question of whether nucleolar targeting alone is sufficient to enhance the level of sumoylated p53. To test this possibility, we fused the NoLS of MDM2 (residue 466-473, KKLKKRNK) to the N terminus of human p53. Fluorescence staining of the NoLS-p53 fusion confirmed partial accumulation in the nucleolus of transfected H1299 and U2OS cells (Figure 8a) .
The results of sumoylation assay using the NoLS-p53 fusion protein showed that direct targeting of p53 to the nucleolus only resulted in slight increase of p53 Figure 7 Nucleolar targeting of p53 by MDM2 and ARF correlates with enhanced sumoylation. U2OS cells were cotransfected with indicated plasmid combinations and stained for p53 (green) and MDM2 (red) by double immunofluorescence staining. The locations of nucleoli were confirmed by phase contrast photography or by staining for nucleolin in separate experiments (not shown). P53 was partially targeted to the nucleolus by ARF and MDM2, which required the 102-116 region of ARF. The MDM2 D222-437 mutant was localized to the nucleolus without ARF and targeted p53 sumoylation and nucleolar localization independent of ARF MDM2-ARF complex regulates p53 sumoylation L Chen and J Chen sumoylation when transfected alone or with MDM2. However, cotransfection with ARF resulted in strong sumoylation of NoLS-p53 (Figure 8b ). Further tests showed that sumoylation of NoLS-p53 remained very inefficient when coexpressed with ARF1-64 fragment (Figure 8c ). However, in the presence of MDM2 and ARF, sumoylation of NoLS-p53 was significantly stronger than p53. Therefore, nucleolar targeting of p53 was not sufficient for sumoylation and did not complement the ARF1-64 fragment in trans, but significantly increased sumoylation efficiency in the presence of ARF and MDM2. These results suggest that the N-and C-terminal domains of ARF have to function in their natural context in order to promote p53 sumoylation. Furthermore, the C-terminal domain of ARF provides other functions in addition to nucleolar targeting of p53.
ARF does not protect p53 and MDM2 from desumoylation by SENP1
The ability of MDM2 and ARF to stimulate p53 sumoylation may be due to increase of sumoylation efficiency by targeting to the nucleolus, or by protection of sumoylated p53 from desumoylating proteases. To test whether the latter mechanism is responsible, a recently isolated desumoylating enzyme SENP1 was cotransfected with p53 (Gong et al., 2002) . The results showed that SENP1 cotransfection significantly reduced the level of sumoylated p53 and MDM2, indicating that both are substrates for SENP1 (Figure 9a and b) . However, SENP1 overexpression was able to prevent sumoylation of p53 and MDM2 even in the presence of ARF (Figure 9a and b). Immunofluorescence staining confirmed that SENP1 did not affect the ability of ARF to target MDM2 and p53 to the nucleolus (data not shown). This result argues against the possibility that ARF protects p53 and MDM2 from desumoylating enzymes by sequestering them in the nucleolus. However, we cannot exclude the possibility that SENP1 overexpression desumoylated p53 and MDM2 before they were sequestered into the nucleolus. 
Discussion
The results described above show that the level of p53 sumoylation is regulated by MDM2 and ARF through a mechanism that requires formation of the p53-MDM2-ARF complex. Furthermore, ARF expression also increases the level of sumoylated MDM2. The nucleolar targeting function of ARF appears to be important for stimulating p53 and MDM2 sumoylation. The previously defined NoLS signal of ARF (82-101) is important for promoting MDM2 sumoylation and nucleolar targeting, whereas an additional conserved region (102-116) is important for promoting p53 sumoylation and nucleolar localization in the presence of MDM2. These results demonstrate that in addition to inhibiting MDM2-mediated ubiquitination of p53, ARF also has a novel function of stimulating p53 sumoylation through binding to MDM2. Nucleolar localization of ARF and sequestration of MDM2 to the nucleolus are obvious features of ARF (Weber et al., 1999 (Weber et al., , 2000 . However, their functions are still not understood. Our results show that a functional consequence of nucleolar targeting is to increase the level of sumoylated p53.
Although it is still unclear whether ARF and MDM2 act by stimulating the rate of p53 sumoylation or by inhibiting desumoylation, the results appear to favor the first mechanism. First, overexpression of the desumoylating enzyme SENP1 abrogates p53 and MDM2 sumoylation in the presence of ARF, suggesting that nucleolar targeting by ARF is not sufficient to prevent desumoylation of p53. Second, direct targeting of p53 to the nucleolus using the MDM2 NoLS signal is not sufficient for enhanced sumoylation. However, NoLSp53 is sumoylated at much higher levels than wild-type p53 in the presence of MDM2 and ARF. This observation suggests that nucleolar targeting facilitates p53 sumoylation, but additional functions of MDM2 and ARF are also required. A model we currently favor is that ARF interaction with MDM2 increases its ability to recruit certain sumoylation cofactors in the nucleolus, which promotes sumoylation of MDM2 and p53. The MDM2 D222-437 deletion may mimic the effect of ARF binding, enabling it to target p53 to the nucleolus and increase sumoylation independent of ARF. The in vitro sumoylation assay used in the current study clearly did not simulate any aspects of nucleolar involvement, which may explain its inability to detect the effects of MDM2 and ARF in vitro. Establishing a cell-free sumoylation assay that recapitulates the effect of ARF and MDM2 will be important for further investigation of the mechanism.
An important unresolved question is the function of p53 and MDM2 sumoylation. Previous studies showed that sumoylation of p53 had very moderate positive effects on its transcription activation function (Melchior and Hengst, 2002) . The ability of MDM2 to promote p53 (wt and p53 386R mutant) ubiquitination is not significantly affected by overexpression of SENP1 (our unpublished result), suggesting that sumoylation of MDM2 or p53 does not regulate p53 ubiquitination. Furthermore, overexpression of SENP1 stimulates the transcription activation function of both wild-type p53 and p53 386R mutant by 2-3-fold (unpublished observation), suggesting that the stimulation is not through modulation of p53 sumoylation level. However, negative results in these assays do not preclude p53 sumoylation playing a role in regulating certain aspects of its tumor suppressor function. The level of sumoylated p53 is a small fraction of total p53 in the cell (possibly o5%). Therefore, the impact of this modification on p53 function may not be evident by the transactivation assay. Furthermore, if sumoylated p53 is mainly concentrated in the nucleolus, it is unlikely to regulate RNA polymerase II-mediated transcription. Whether such modified p53 is involved in other novel functions such as regulation of ribosome assembly or ribosomal RNA transcription or processing remains to be investigated.
Materials and methods
Cell lines and plasmids
H1299 (nonsmall-cell lung carcinoma, p53 null) and U2OS (osteosarcoma, p53 wild type, ARF deficient) cells were maintained in DMEM medium with 10% fetal bovine serum. Plasmids expressing His6-ubiquitin, His6-SUMO-1, and HA-SUMO-1 were kindly provided by Drs David Lane, Ronald Hay, and Honggang Wang (Rodriguez et al., 1999; Xirodimas et al., 2002a) . ARF deletion and point mutants were kind gifts from Dr Yue Xiong (Zhang and Xiong, 1999) . SENP1 was kindly provided by Dr Edward Yeh (Gong et al., 2002) . MDM2 mutations were described previously (Chen et al., 1993,) . Point mutants of p53 and MDM2 were created using the Quick Change kit from Stratagene. All p53, MDM2, and ARF constructs used in this study were of human origin. His6-p53 and NoLS-p53 fusion proteins were created by PCR amplification of p53 using 5 0 primers that introduced the additional amino-acid sequences to the N-terminus of p53.
Western blot
Cells were lysed in lysis buffer (50 mm Tris-HCl (pH 8.0), 5 mm EDTA, 150 mm NaCl, 0.5% NP40, 1 mm PMSF), centrifuged for 5 min at 10,000 g, and the insoluble debris were discarded. Cell lysate (10-50 mg protein) was fractionated by SDS-PAGE and transferred to Immobilon P filters (Millipore). The filter was blocked for 1 h with phosphate-buffered saline (PBS) containing 5% nonfat dry milk and 0.1% Tween-20. MDM2 was detected by monoclonal antibody 3G9 or 4B11 (Chen et al., 1993) ; p53 was detected by monoclonal antibody DO-1 (Pharmingen); SENP1 was detected by an antipeptide rabbit antibody (Abgent). The filter was developed using ECL-plus reagent (Amersham). Although this procedure was mainly used to determine the expression levels of transfected p53 and MDM2, sumoylated or ubiquitinated p53 bands also appeared in some blots, but were much less reproducible than samples purified in the presence of 6 m guanidinium. This may be due to the presence of active SUMO and ubiquitin isopeptidases in the lysate.
In vivo sumoylation and ubiquitination assays H1299 cells in 9 cm plates were transfected with 5 mg each of His6-SUMO-1 or His6-ubiquitin expression plasmids, 5 mg of human p53, MDM2, and ARF expression plasmids using the conventional calcium phosphate precipitation method. At 32 h after transfection, cells from each plate were collected into two aliquots. One aliquot was used for conventional Western blot to confirm expression of transfected proteins. The second aliquot was used for purification of His6-tagged proteins by Ni 2 þ -NTA beads. The cell pellet was lysed in buffer A (6 m guanidinium-HCl, 0.1 m Na 2 HPO 4 /NaH 2 PO 4 , 0.01 m Tris-Cl pH 8.0, 5 mm imidazole, 10 mm b-mercaptoethanol) and incubated with Ni 2 þ -NTA beads (Qiagen) for 4 h at room temperature. The beads were washed with buffer A, B (8 m urea, 0.1 m Na 2 PO 4 /NaH 2 PO 4 , 0.01 m Tris-Cl pH 8.0, 10 mm b-mercaptoethanol), C (8 m urea, 0.1 m Na 2 PO 4 /NaH 2 PO 4 , 0.01 m Tris-Cl pH 6.3, 10 mm b-mercaptoethanol), and the bound proteins were eluted with buffer D (200 mm imidazole, 0.15 m Tris-Cl pH 6.7, 30% glycerol, 0.72 m b-mercaptoethanol, 5% SDS). The eluted proteins were analysed by Western blot for the presence of conjugated p53 by DO-1 antibody and MDM2 by 3G9 antibody (Chen et al., 1993) . The 4B11 antibody was used to detect the MDM2 D222-437 mutant. For detection of endogenous SUMO1 or HA-SUMO1 conjugated to His6-p53, Ni 2 þ -NTA-purified His6-p53 was analysed by Western blotting using an anti-SUMO1 antibody (Zymed).
In vitro sumoylation assay
Human p53, MDM2, and ARF were translated in vitro using the TNT-coupled rabbit reticulocyte lysate system (Promega) in the presence of 35 S-methionine. In vitro translation product (2 ml) was used in a 20 ml reaction containing 25 mm Tris-Cl (pH 7.5), 4 mm MgCl 2 , 1 mm DTT, 3 mm ATP, 500 ng purified UbcH9, 5 mg purified SUMO-1, and 16 mg of Hela Fraction II (AG Scientific). The mixture was incubated for 2 h at 301C, boiled in SDS sample buffer and fractioned by SDS-PAGE. Radiolabeled proteins were detected by autofluorography.
Immunofluorescence staining
Cells cultured on chamber slides were transfected with indicated combinations of p53, MDM2, and ARF expression plasmids using Lipofectamine-Plus reagents (Life Technologies). At 24 h after transfection, cells were fixed with acetonemethanol (1 : 1) for 3 min at room temperature, blocked with PBS þ 10% normal goat serum (NGS) for 20 min, and incubated with a mixture of anti-MDM2 2A9 hybridoma supernatant (1/50 dilution) and rabbit-anti-p53 antibody FL393 (0.5 mg/ml) in PBS þ 10% NGS for 2 h. The slides were washed with PBS þ 0.1% Triton X-100, incubated with FITCgoat-anti-rabbit IgG and rhodamine-goat-anti-mouse IgG in PBS þ 10% NGS for 1 h, washed with PBS þ 0.1% Triton X-100 and mounted.
